ArticleTherapeutic advances in drug safety2026
Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case-control study.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While bleeding is an inherent risk of all anticoagulant therapies, individual susceptibility varies considerably. Rivaroxaban, a direct oral anticoagulant widely used for thromboembolic prevention, is associated with substantial interindividual variability in bleeding risk, posing an ongoing clinical challenge. Objectives: To investigate associations between pharmacogenetic variants in five pharmacokinetic (PK) and nine pharmacodynamic (PD) genes, along with clinical factors, and bleeding outcomes in Thai patients receiving rivaroxaban. Design: A retrospective case-control study was conducted among 91 patients with atrial fibrillation, including 27 who experienced bleeding events. Methods: Genetic variants in PK and PD genes were genotyped using the MassARRAY Results: The CT genotype of Conclusion: Bleeding risk in Thai patients receiving rivaroxaban appeared to be influenced by both pharmacogenetic variants, particularly the Trial registration: As a retrospective non-interventional study, this work was not registered in a clinical trial registry. Ethical approval was obtained (COA No. 1657/2022).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.